Click on image to view larger version.

Figure 5 Infarct size plotted against risk zone volume for control hearts and hearts with four cycles of postconditioning alone or after treatment with either PD98059, glibenclamide (Glib), N-nitro-L-arginine methyl ester (L-NAME), or 5-hydroxydecanoate (5-HD). Regression lines for the control group and postconditioned hearts treated with PD98059, Glib, L-NAME, or 5-HD were significantly different from that for hearts subjected only to postconditioning (p < 0.001).